Table 1.
Basic characteristics of study participants according to post-diagnostic marine ω-3 polyunsaturated fatty acid (MO3PUFA) intake*
| Variable | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 |
|---|---|---|---|---|
| No. of participants | 445 | 425 | 437 | 428 |
| Age, year | 58.2±12.0 | 57.2±11.9 | 58.5±10.6 | 58.1±10.6 |
| Sex | ||||
| Women | 216 (49) | 205 (48) | 212 (49) | 205 (48) |
| Men | 229 (51) | 220 (52) | 225 (51) | 223 (52) |
| Study arm | ||||
| FOLFOX | 219 (49) | 205 (48) | 212 (49) | 214 (50) |
| FOLFOX plus cetuximab | 226 (51) | 220 (52) | 225 (51) | 214 (50) |
| Tumor subsite | ||||
| Proximal colon | 236 (53) | 238 (56) | 220 (50) | 207 (48) |
| Distal colon | 206 (46) | 179 (42) | 205 (47) | 219 (51) |
| Both | 3 (1) | 7 (2) | 12 (3) | 2 (1) |
| No. of affected nodes | ||||
| 1-3 | 261 (59) | 249 (59) | 253 (58) | 246 (57) |
| ≥4 | 184 (41) | 176 (41) | 184 (42) | 182 (43) |
| Histology | ||||
| High | 117 (26) | 100 (24) | 118 (27) | 105 (25) |
| Low | 328 (74) | 325 (76) | 319 (73) | 323 (75) |
| MMR Status | ||||
| pMMR | 375 (88) | 351 (86) | 358 (86) | 369 (89) |
| dMMR | 49 (12) | 56 (14) | 58 (14) | 48 (11) |
| BRAF Mutation | ||||
| Mutant | 66 (16) | 51 (13) | 58 (14) | 54 (13) |
| Wildtype | 348 (84) | 342 (87) | 344 (86) | 349 (87) |
| KRAS Mutation | ||||
| Mutant | 143 (33) | 139 (34) | 155 (37) | 146 (36) |
| Wildtype | 288 (67) | 265 (66) | 259 (63) | 263 (64) |
| ECOG Performance Score | ||||
| 0 | 340 (76) | 316 (74) | 327 (75) | 340 (79) |
| 1 | 103 (23) | 103 (24) | 106 (24) | 85 (20) |
| 2 | 2 (1) | 6 (2) | 4 (1) | 3 (1) |
| Aspirin Use | ||||
| None | 295 (73) | 259 (68) | 256 (65) | 254 (68) |
| Low-dose | 67 (17) | 77 (20) | 88 (22) | 81 (22) |
| Full dose | 40 (10) | 47 (12) | 49 (13) | 39 (10) |
| Regular Multivitamin Use | ||||
| 0=NO | 231 (55) | 223 (57) | 201 (50) | 209 (52) |
| 1=YES | 187 (45) | 168 (43) | 204 (50) | 190 (48) |
| Smoking Frequency | ||||
| Never | 198 (45) | 213 (50) | 215 (49) | 208 (49) |
| Past | 200 (45) | 185 (44) | 193 (44) | 195 (46) |
| Current, ≤20 cigs/day | 29 (7) | 18 (4) | 24 (6) | 19 (4) |
| Current, >20 cigs/day | 15 (3) | 9 (2) | 3 (1) | 5 (1) |
| Alcohol Consumption | ||||
| Never | 132 (30) | 120 (28) | 134 (31) | 128 (30) |
| Past | 144 (33) | 120 (28) | 126 (29) | 123 (29) |
| Current | 167 (37) | 185 (44) | 176 (40) | 176 (41) |
| Vigorous physical activity | ||||
| Never | 327 (74) | 278 (66) | 296 (68) | 254 (60) |
| Monthly | 91 (21) | 115 (27) | 100 (23) | 127 (30) |
| Weekly | 23 (5) | 29 (7) | 37 (9) | 46 (10) |
| BMI, kg/m2 | ||||
| <18.5 | 6 (1) | 3 (1) | 9 (2) | 3 (1) |
| 18.5-22.4 | 55 (12) | 49 (12) | 59 (14) | 47 (11) |
| 22.5-24.9 | 72 (16) | 68 (16) | 63 (14) | 59 (14) |
| 25.0-29.9 | 166 (37) | 160 (38) | 152 (35) | 165 (39) |
| ≥30 | 145 (33) | 142 (33) | 154 (35) | 152 (35) |
| Total MO3PUFA, g/day | 0.025±0.008 | 0.045±0.007 | 0.067±0.01 | 0.13±0.006 |
| Women | 0.021±0.007 | 0.039±0.005 | 0.063±0.009 | 0.12±0.005 |
| Men | 0.028±0.009 | 0.049±0.006 | 0.071±0.008 | 0.14±0.006 |
| EPA, mg/day | 6±3 | 12±4 | 20±5 | 44±22 |
| DHA, mg/day | 15±5 | 27±5 | 39±7 | 72±29 |
| DPA, mg/day | 3±2 | 6±2 | 9±3 | 16±7 |
| Total omega-3 PUFA, g/day | 1.1±0.6 | 1.1±0.4 | 1.2±0.4 | 1.3±0.4 |
| Total omega-6 PUFA, g/day | 10.3±3.1 | 10.3±2.7 | 10.8±2.6 | 10.9±2.9 |
| Vitamin D, IU/day | 334±251 | 301±233 | 326±229 | 334±226 |
| Calcium, mg/day | 870±483 | 871±467 | 850±450 | 863±470 |
| Total Fiber, g/day | 23.4±9.9 | 25.1±8.7 | 25.7±8.6 | 28.0±10.0 |
| Fish, g/day | 3.5±2.4 | 8.1±4.1 | 14.4±5.6 | 35.7±22.0 |
| Processed red meat, g/day | 31.7±33.1 | 29.6±28.1 | 29.7±26.2 | 26.3±29.3 |
Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid.
*
Mean±SD is shown for continuous variables. N (%) is shown for categorical variables. For some variables, the number of participants across all categories does not sum to the total due to missing data.